Heart disease is often linked to high cholesterol, obesity, or lack of exercise. However, there is mounting evidence that suggests that mental health plays a crucial role in cardiovascular well-being. Stress, anxiety, and depression can silently strain the heart, increasing the risk of serious complications.

A recent study, published in Nature Human Behaviour, showed that loneliness has a significant impact on proteins present in a person's blood. For the study, researchers used data from more than 42,000 participants to explore whether the 9.3% who reported social isolation and 6.4% who reported loneliness had different levels of proteins in their blood compared with those who did not. The researchers then studied data that tracked the health of participants over an average 14-year period.

"We found around 90% of these proteins are linked to the risk of mortality," Dr Chun Shen, Fudan University in China, who is also the lead researcher said. "In addition, about 50% of the proteins were linked to cardiovascular disease, type 2 diabetes and stroke," he added.

Dr Shrey Kumar Srivastav, senior consultant at Sharda Hospital, said that subtle symptoms of heart disease, such as fatigue, shortness of breath, swelling in the lower legs, dizziness, and jaw pain, are often overlooked or attributed to stress and ageing. "Women, in particular, may experience atypical signs like extreme fatigue, indigestion, or upper abdominal pain instead of classic chest pain, leading to delayed diagnosis," he added.

Can Mental Health Issues Trigger Heart Diseases?

Chronic stress can trigger harmful cardiovascular effects, including elevated blood pressure, increased heart rate, and inflammation—key contributors to heart disease. Anxiety and depression further impact heart health by disrupting sleep patterns, raising stress hormone levels, and encouraging unhealthy habits like poor diet and inactivity.

Mental health issues like depression and anxiety have a profound impact on the heart. They don’t just affect emotions but can increase inflammation and put extra strain on the cardiovascular system, warns Dr Srivastav.

Certain risk factors, such as obesity and diabetes, disproportionately affect women, making them more vulnerable to heart failure with preserved ejection fraction (HFpEF). However, due to gender-specific symptom variations, heart disease in women often goes undiagnosed for longer.

Obesity is more prevalent in women than men and is a major risk factor for heart failure. Diabetes, too, has a greater impact on women’s heart health, yet diagnosis and treatment delays are common. Addressing this gap requires increasing awareness, training healthcare providers, and promoting early diagnostic tools,” explains Dr Srivastav.

How Can You Protect Your Heart?

A simple yet effective way to support heart health is by committing to a brisk 30-minute walk daily. Walking not only helps regulate blood pressure and manage weight but also improves circulation and reduces stress.

"Regular physical activity, paired with a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins, significantly lowers cardiovascular risks," advises Dr Srivastav.

Heart disease can often go undetected until a major event occurs, making routine screenings essential.

- For women: Begin screenings around age 30 and continue with regular checkups.

- For men: Start screenings at age 35.

Health screenings, including blood pressure checks, cholesterol tests, and electrocardiograms (ECGs), are critical for early detection of silent heart conditions.

GLP-1 weight-loss drugs have taken the world by storm. One new entrant is Eli Lilly's retatrutide, which has demonstrated bariatric surgery-level weight loss.

Retatrutide is not yet FDA-approved or commercially available; it is expected to be available by the end of 2026.

According to a media report, Eli Lilly and the Food and Drug Administration (FDA) have allowed one person to gain access to the drug through the company's "compassionate use" program. It is generally used by patients with serious and immediately life-threatening medical issues to get access to experimental treatments.

STAT News, citing sources, reported that a request for drug access was made in April for a 79-year-old, well-connected man, and indicated that the person could be US President Donald Trump, who turned 80 a week ago.

What Did White House Say

The White House has aggressively denied the claim.

"This application was not for the President," said, White House spokesperson Kush Desai, while blasting STAT on X..

STAT claimed that "during the Covid-19 pandemic, Trump was notably one of the first people administered an antibody treatment from Regeneron after he contracted the virus, via this same compassionate use pathway".

Further, the media outlet cited that Ranganath Muniyappa, a senior clinician at the National Institutes of Health, had requested the drug to treat a patient for refractory obesity with obstructive sleep apnea and pulmonary hypertension, noting it inquired whether Trump has those conditions.

In response, Desai referred to a White House memo on Trump's most recent medical evaluation that did not contain any mention of obstructive sleep apnea or pulmonary hypertension.

Also read: President Donald Trump Remains In Excellent Health, Says White House

Did Trump take Ozempic?

Earlier this year, Trump told The New York Times that he had not taken GLP-1 drugs like Wegovy and Ozempic but said, "I probably should."

Notably, Trump's latest physical exam revealed the president weighed 238 pounds, a 14-pound increase from April 2025 that nearly reached the threshold of clinical obesity.

Trump's health has been under increased scrutiny as he turned 80 this year and has been frequently seen with swollen ankles and bruises on his hands.

What Is Retatrutide?

Read More: US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine

Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. The drug aims to maximize weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.

Unlike Zepbound, which is a double agonist, retatrutide, mimics glucagon along with GLP-1. It thus, works like a triple agonist.

In the third phase of clinical trial, the drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial.

Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.

Health officials in Australia have confirmed a third case of the deadly H5 bird flu in a migratory bird on Australia's southern coast, taking the total number of cases to three. The first two cases were reported in Western Australia.

The third case of avian influenza was recorded in a giant petrel found at Knights Beach on the Fleurieu Peninsula.

According to South Australian Premier Peter Malinauskas, the state recorded two sick birds that came into the care of a local wildlife rescue group on June 14, ABC News reported.

"Once that was drawn to the attention on June 19 to the relevant authorities in South Australia, we responded quickly and enabled and facilitated active testing of those birds for H5 bird flu," the premier said.

"This afternoon we received those results and they confirmed that one of those birds was negative and one of them was positive."

He also stressed the cases have no connection, as it involved a migratory bird.

"It's also important to emphasize that this is a migratory bird. This is not a contamination or infection that has come from WA to SA."

Further, Malinauskas noted that the volunteers who handled the birds would be given anti-viral medication if necessary.

He urged people who see unwell or dead birdlife to "avoid, record and report" via hotline 1800 675 888.

Also read: France Confirms First Ebola Case; Congo Outbreak Grows to 1,094 Cases, 277 Deaths

Malinauskas said two other sick birds found at Fowlers Bay yesterday had tested negative for the virus.

It comes after two birds were confirmed to have the disease near the town of Esperance in Western Australia.

The country's Chief Veterinary Officer, Dr Beth Cookson, said there was no indication it had spread from those two birds.

Genomic sequencing shows the virus in that initial bird — a brown skua — is related to an outbreak on Heard Island and McDonald Islands.

Why Australia Had Remained Bird Flu-Free

Until now, Australia was the only continent where the H5N1 strain, the highly contagious strain of H5 bird flu, had not been detected. Although the virus has circulated across Asia since the 1990s and reached Antarctica in 2024, Australia had remained unaffected.

According to Dr Michelle Wille, ARC Future Fellow at the University of Melbourne, Australia's unique bird migration patterns likely delayed the virus's arrival.

"There are no duck species which routinely migrate between Australia and Asia, nor are there ducks that migrate through Antarctica," Wille wrote in The Conversation.

However, evidence suggests other seabirds—including gulls, skuas and giant petrels—may have helped carry the virus over long distances across Antarctica and subantarctic regions, eventually bringing it closer to Australia, he said.

As per the latest update, Australian scientists believe that the H5 bird flu strain killed more than 13,000 elephant seal pups after infecting a breeding colony on the remote Heard and McDonald Islands, one of Australia's external territories in the sub-Antarctic.

Read More: Sri Lanka Dengue Outbreak Nears 50,000 Cases: Prevention Tips You Need to Know

Can Bird Flu Affect Humans?

Despite the rise in cases, Agricultural Minister Julie Collins assured the public that there is no immediate threat to human health.

"Chicken meat and eggs remain safe for consumption when properly prepared," she noted.

While human infections remain rare, they can occur through direct and unprotected contact with infected birds, animals, or contaminated environments.

Although severe human cases have historically shown a mortality rate of around 50%, sustained human-to-human transmission has not been observed.

How to Protect Yourself

Health authorities recommend the following precautions:

• Avoid direct contact with sick or dead wild birds and other animals whenever possible.
• Observe wildlife from a safe distance.
• Wear appropriate personal protective equipment (PPE) if handling sick or dead birds or animals is unavoidable.
• Avoid touching surfaces contaminated with bird droppings, saliva, mucus, litter, or bedding from infected or suspected animals.
• Do not consume raw milk or raw milk products, particularly from animals suspected or confirmed to be infected with avian influenza.
• Report sick or dead birds to local authorities if encountered.

French health officials have confirmed the first positive Ebola case in a doctor returning from a humanitarian mission in Congo.

It is the country's first case of the virus during the current outbreak, and the first in Europe. It is also the first case outside Africa in the 2026 outbreak.

The health ministry "confirms today the identification of a first positive case of Ebola virus disease on national territory", it said.

The patient, identified in mainland France, is being isolated and authorities are conducting contact tracing, the ministry said, adding that the risk to the general European population was low, AFP reported.

Congo Outbreak Reaches Record First-Month Total

Also read: 'Omega Block' Causing Europe Heatwave; France Worst Hit

The confirmed cases in the Ebola outbreak in the Democratic Republic of Congo have reached the highest total ever recorded during the first month of an outbreak in Africa, according to the World Health Organization (WHO).

As of June 22, confirmed Ebola cases in Congo had risen to 1,094 and deaths to 277, according to the DRC Ministry of Health. The WHO raised concerns about the rapid spread of the deadly virus and the challenges facing containment efforts.

“This is the largest number of confirmed cases in the first month of an Ebola disease outbreak in Africa,” said Dr Abdirahman Mahamud, Director, Health Emergency Alert and Response Operations at WHO, during a press briefing in Geneva.

"What is important is we need to scale up and this outbreak is moving faster than us," he told reporters after returning from Bunia last week.

Signs of Progress Amid Challenges

Read More: Teplizumab: UK NHS To Roll Out World-First Drug To Delay Onset Of Type 1 Diabetes

Mahamud also noted signs of hope, highlighting a quick increase in the number of Ebola beds to over 500 in the past fortnight and signs that community resistance and violent resistance to Ebola responders was beginning to abate.

Taking to social media platform X, Dr Tedros shared that “100 patients have recovered so far, which shows that for many, the virus can be stopped with timely health care”.

He also lauded efforts being made to “increase the number of Ebola Treatment Centres and lab and surveillance capacities, to train more health workers on clinical care and infection prevention and control, and to improve the understanding and involvement of communities”.

However, he highlighted the need to do more.

"More treatment centers, more trained health and care workers, more testing, more teams from within communities supporting communities. We need sustained and safe access to reach all affected people”.

US Supports Experimental Treatment Trials

Meanwhile, the US has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials to fight the widening Ebola outbreak in Congo, a Department of Health and Human Services spokesperson said, a shift from its position of making the drug available only to Americans, Reuters reported.

While the spokesperson declined to comment on the number of doses, it said that the drug is being made available for compassionate use in Congo as well as to advance a clinical trial in the outbreak region.

There are currently no approved vaccines or treatments for the Bundibugyo strain of Ebola.

This marks the first time the US government has indicated it plans to directly support clinical trials of the antibody treatment known as MBP134 from San Diego-based Mapp by providing stockpiled doses.

The Mapp drug is expected to be among the first treatments to be tested in the outbreak.

Trials of the Mapp drug and two Gilead Sciences antivirals are due to begin in the coming weeks, according to the WHO and scientists involved in the testing, the report said.